Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 98.97% is 131% above its 5-year average of -322.18%, near the high end of its 5-year range (-2548.47%–199.76%).
24.91% above its 12-month average of 79.23%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 109.84%.
GROSS MARGIN
98.97%
GROSS MARGIN AVG TTM
79.23%
GROSS MARGIN AVG 3Y
-60.24%
GROSS MARGIN AVG 5Y
-322.18%
GROSS MARGIN AVG 10Y
-73.14%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.91%
CURRENT VS 3Y AVG
+264.30%
CURRENT VS 5Y AVG
+130.72%
CURRENT VS 10Y AVG
+235.31%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
45.27%
median of 458 covered companies
CURRENT VS SECTOR MEDIAN
+118.60%
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.46B
Gross Margin
98.97%
TTM Avg
79.23%
3Y Avg
-60.24%
5Y Avg
-322.18%
Market Cap
$1.45B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.43B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.52B
Gross Margin
57.87%
TTM Avg
56.73%
3Y Avg
61.85%
5Y Avg
-49.66%
Market Cap
$1.39B
Gross Margin
-91.00%
TTM Avg
-566.75%
3Y Avg
-1506.60%
5Y Avg
-994.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.46B | 98.97% | 79.23% | -60.24% | -322.18% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 17.33% | 13.16% | 12.65% | 13.31% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | 0.00% | 0.00% | 0.00% | 0.00% |
| Innoviva, Inc. (INVA)vs › | $1.52B | 73.09% | 81.06% | 86.06% | 90.71% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 57.87% | 56.73% | 61.85% | -49.66% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -91.00% | -566.75% | -1506.60% | -994.02% |
| Certara, Inc. (CERT)vs › | $1.57B | 58.33% | 60.70% | 60.53% | 60.29% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
99.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 109.84% |
| 2026-03-31 | 97.61% |
| 2025-12-31 | 199.76% |
| 2025-09-30 | 58.85% |
| 2025-06-30 | -69.90% |
| 2025-03-31 | -48.28% |
| 2024-12-31 | 1.22% |
| 2024-09-30 | -40.63% |
| 2024-06-30 | -282.80% |
| 2024-03-31 | -415.98% |
| 2023-12-31 | -272.29% |
| 2023-09-30 | -830.62% |
| 2023-06-30 | -851.53% |
| 2023-03-31 | -2444.18% |
| 2022-12-31 | -243.33% |
| 2022-09-30 | -1606.42% |
| 2022-06-30 | -1614.14% |
| 2022-03-31 | -2221.24% |
| 2021-12-31 | -2548.47% |
| 2021-09-30 | -6.37% |
| 2021-06-30 | 15.70% |
| 2021-03-31 | -115.04% |
| 2020-12-31 | 64.05% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | -39.79% |
| 2019-12-31 | -614.20% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -447.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -257.66% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -153.53% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | -2.93% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -82.14% |
| 2016-09-30 | -2.12% |
| 2016-06-30 | 60.09% |
| 2016-03-31 | 1.64% |
| 2015-12-31 | -62.11% |
| 2015-09-30 | 4.30% |
| 2015-06-30 | 31.89% |
| 2015-03-31 | 25.21% |
| 2014-12-31 | 29.69% |
| 2014-09-30 | 65.37% |
| 2014-06-30 | 51.50% |
| 2014-03-31 | -3.43% |
